Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UNC4241 is a **pan-TAM small molecule inhibitor** that targets the TAM family of receptor tyrosine kinases: TYRO3, AXL, and MERTK. It is characterized by potent inhibition with IC50 values of 1.4 nM for MERTK, 5.4 nM for AXL, and 2.3 nM for TYRO3. UNC4241 has pharmacokinetic properties suitable for once-daily oral dosing in mice. It has demonstrated activity in tumor models by delaying tumor growth, promoting T cell infiltration, augmenting anti-PD-1 immunotherapy, and reversing the immunosuppressive functions of myeloid-derived suppressor cells (MDSCs). UNC4241 also inhibits FLT3 kinase. It is used in research settings to study the immuno-tolerant tumor microenvironment and cancer immunotherapy resistance[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UNC4241.